News
06-06-2011, 04:11 AM
Following the conclusion of a series of meetings with the United States Food and Drug Administration (FDA), GTx, Inc. announced today the clinical trial design for the two Phase III Ostarine registration studies for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer (NSCLC).
More... (http://www.news-medical.net/news/20110606/GTx-to-initiate-two-Ostarine-Phase-III-trial-for-treatment-of-muscle-wasting-in-patients-with-NSCLC.aspx)
More... (http://www.news-medical.net/news/20110606/GTx-to-initiate-two-Ostarine-Phase-III-trial-for-treatment-of-muscle-wasting-in-patients-with-NSCLC.aspx)